Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
40
ASND Quote, Financials, Valuation and Earnings
Last price:
$200.02
Seasonality move
:
19.56%
Day range:
$197.16 - $202.78
52-week range:
$118.03 - $229.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.72x
P/B ratio:
--
Volume:
1.8M
Avg. volume:
773.5K
1-year change:
45.19%
Market cap:
$12.2B
Revenue:
$393.3M
EPS (TTM):
-$4.25
Analysts' Opinion
-
Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $262.71, Ascendis Pharma A/S has an estimated upside of 31.36% from its current price of $199.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $223.94 representing 100% downside risk from its current price of $199.99.
Fair Value
-
According to the consensus of 13 analysts, Ascendis Pharma A/S has 31.36% upside to fair value with a price target of $262.71 per share.
ASND vs. S&P 500
-
Over the past 5 trading days, Ascendis Pharma A/S has underperformed the S&P 500 by -9.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ascendis Pharma A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ascendis Pharma A/S has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Ascendis Pharma A/S reported revenues of $249.6M.
Earnings Growth
-
Ascendis Pharma A/S has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Ascendis Pharma A/S reported earnings per share of -$1.17.
Enterprise value:
12.5B
EV / Invested capital:
--
Price / LTM sales:
16.72x
EV / EBIT:
--
EV / Revenue:
17.40x
PEG ratio (5yr expected):
-0.47x
EV / Free cash flow:
-101.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$609M
Return On Assets:
-20.57%
Net Income Margin (TTM):
-35.52%
Return On Equity:
-880.05%
Return On Invested Capital:
-34.4%
Operating Margin:
5.15%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $163.2M | $354.5M | $720.7M | $63.5M | $249.6M | |
| Gross Profit | $115.9M | $285.4M | $609M | $47.4M | $219.4M | |
| Operating Income | -$604M | -$342.4M | -$156.5M | -$106.3M | $12.9M | |
| EBITDA | -$584.2M | -$322.7M | -$137.3M | -$101.5M | $17.5M | |
| Diluted EPS | -$11.39 | -$8.10 | -$4.25 | -$1.89 | -$1.17 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.1B | $776M | $1.1B | $1.2B | |
| Total Assets | $1.4B | $1.2B | $924.5M | $1.2B | $1.4B | |
| Current Liabilities | $134.6M | $139.9M | $225.3M | $935.8M | $1.2B | |
| Total Liabilities | $245.3M | $805.1M | $1B | $1.3B | $1.6B | |
| Total Equity | $1.2B | $442.4M | -$77.7M | -$108.6M | -$204.5M | |
| Total Debt | $118.6M | $522.3M | $692.4M | $849.3M | $890.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$602.4M | -$277M | -$117.7M | -$61.4M | $1.6M | |
| Cash From Investing | $302.2M | $11.1M | -$6.1M | -$519K | -$259.4K | |
| Cash From Financing | $145.6M | $472.4M | $33.3M | $463.6M | $43.3M | |
| Free Cash Flow | -$608.9M | -$278M | -$123.9M | -$61.9M | $1.3M | |
ASND
Sector
Market Cap
$12.2B
$27.9M
Price % of 52-Week High
86.98%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-0.93%
-1.49%
1-Year Price Total Return
45.19%
-16.66%
Beta (5-Year)
0.448
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$207.47
200-day SMA
Buy
Level
$182.32
Bollinger Bands (100)
Sell
Level
192.48 - 209.22
Chaikin Money Flow
Buy
Level
27.6M
20-day SMA
Sell
Level
$206.98
Relative Strength Index (RSI14)
Sell
Level
44.76
ADX Line
Sell
Level
10.16
Williams %R
Neutral
Level
-79.5273
50-day SMA
Sell
Level
$205.78
MACD (12, 26)
Sell
Level
-0.34
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
21.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.3392)
Sell
CA Score
(Annual)
Level (-4.4728)
Sell
Beneish M-Score
(Annual)
Level (-0.6378)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.5657)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
Stock Forecast FAQ
In the current month, ASND has received 13 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ASND average analyst price target in the past 3 months is $262.71.
-
Where Will Ascendis Pharma A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ascendis Pharma A/S share price will rise to $262.71 per share over the next 12 months.
-
What Do Analysts Say About Ascendis Pharma A/S?
Analysts are divided on their view about Ascendis Pharma A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ascendis Pharma A/S is a Sell and believe this share price will drop from its current level to $223.94.
-
What Is Ascendis Pharma A/S's Price Target?
The price target for Ascendis Pharma A/S over the next 1-year time period is forecast to be $262.71 according to 13 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ASND A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ascendis Pharma A/S is a Buy. 13 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ASND?
You can purchase shares of Ascendis Pharma A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ascendis Pharma A/S shares.
-
What Is The Ascendis Pharma A/S Share Price Today?
Ascendis Pharma A/S was last trading at $200.02 per share. This represents the most recent stock quote for Ascendis Pharma A/S. Yesterday, Ascendis Pharma A/S closed at $199.99 per share.
-
How To Buy Ascendis Pharma A/S Stock Online?
In order to purchase Ascendis Pharma A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get ASND Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ASND
Sector
P/E ratio
--
23.85x
PEG ratio
-0.47x
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
16.72x
1.58x
Growth Metrics
ASND
Sector
Revenue growth
292.94%
4.62%
Earnings growth
38.07%
10.5%
Revenue (5-year growth)
92.27%
6.5%
Earnings forecast
$0.47
-$0.21
Profitability
ASND
Sector
Profitability FY 2024
$333.1M
$3.6M
Return on invested capital
-34.4%
-31.87%
Return on assets
-20.57%
-28.18%
Return on equity
-880.05%
-37.63%
Earnings Date
Last Earnings Date
Nov
12
Next Earnings Date
Feb
11
Estimated Next Earnings Date
Feb
11
Balance Sheet
ASND
Sector
Total cash
$633.4M
$26.4M
Short term investments
--
$25.7M
Total assets
$1.2B
$76.9M
Long term debt
$890.2M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
